The mission of the Molecular Oncology Program (MO) is to integrate and coordinate research with a focus on identifying and exploring anti-cancer targets, particularly those that distinguish cancer from noncancer cells based on growth, differentiation and survival. Key accomplishments in this Program include the discovery of a novel small molecule that targets an oncogenic fusion protein, STAG2 as a regulator of chromosomal integrity that is deleted in many cancers, and a novel method to chemically reprogram cancer cells. Continued emphasis is on discovering small molecule probes that may lead to future novel therapeutics and biomarkers. To accomplish this mission, MO members perform research around three themes: Theme 1 focuses on unique genomic events that initiate and sustain cancer growth: mechanisms deregulating chromosomal integrity and the role of oncogenic chromosomal translocations in malignancy. Theme 2 focuses on the immortal lives of cancer cells: studies on cellular immortalization;cancer prevention by dietary components that modulate DNA repair mechanisms;and the effect of nutrients on the activity of mutant p53 and its role in transcriptional activation in DNA repair. Theme 3 focuses on the metastatic mechanisms that allow the spread of cancer: discovering novel regulators of metastatic pathways and identifying useful small molecule inhibitors. Led by Jeffrey Toretsky, MD, and Vicente Notario, PhD, the Program has 17 members and includes faculty from six Georgetown University departments. Total peer review funding is $5.9M (direct) in the last budget year, of which $4M is from NCI. MO members published 210 peer-reviewed publications, of which 35% involved external collaborations and 41% were intra- and/or interprogrammatic, the latter involving collaborations with all three other LCCC Programs. Research on small molecules targeting EWS-FLH and the conditionally reprogrammed cells methodology begun in MO have transitioned to the Experimental Therapeutics or Breast Cancer Programs for clinical trials. Members used all nine Shared Resources;MO research on cell immortalization was developed into a new shared service by the Center. The Cancer Center has added value to the Program through $16M in institutional support over the past funding period facilitating the recruitment and support of two new junior faculty members, by facilitating access to new technologies both within the Cancer Center or through external affiliations with other institutions.

Public Health Relevance

): While the Program is neither disease-specific nor therapy-focused, it develops the basic scientific underpinnings for prevention and targeted therapies across all cancer types. For example, prostate cancer and the human papilloma virus (HPV) are major areas of emphasis investigated by MO researchers that have important regional implications due to the high rate of prostate cancer and HPV infection in our catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA051008-21
Application #
8698913
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2019-04-30
Budget Start
2014-09-09
Budget End
2015-04-30
Support Year
21
Fiscal Year
2014
Total Cost
$38,982
Indirect Cost
$13,913
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Laiakis, Evagelia C; Mak, Tytus D; Strawn, Steven J et al. (2018) Global metabolomic responses in urine from atm deficient mice in response to LD50/30 gamma irradiation doses. Environ Mol Mutagen 59:576-585
O'Neill, Suzanne C; Taylor, Kathryn L; Clapp, Jonathan et al. (2018) Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. J Health Commun 23:679-686
Kim, Sang-Soo; Harford, Joe B; Moghe, Manish et al. (2018) Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46:1424-1440
Wallington, Sherrie; Oppong, Bridget; Dash, Chiranjeev et al. (2018) A Community-Based Outreach Navigator Approach to Establishing Partnerships for a Safety Net Mammography Screening Center. J Cancer Educ 33:782-787
Wärri, Anni; Cook, Katherine L; Hu, Rong et al. (2018) Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes. Cell Death Discov 4:40
Pohlmann, Paula R; Isaacs, Claudine (2018) Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst 110:
Fu, Ying; Silverstein, Shana; McCutcheon, Justine N et al. (2018) An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice. Hepatology 67:159-170
Stires, Hillary; Heckler, Mary M; Fu, Xiaoyong et al. (2018) Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities. Mol Cell Endocrinol 471:105-117
Xiao, David; Zheng, Chaoyi; Jindal, Manila et al. (2018) Medicaid Expansion and Disparity Reduction in Surgical Cancer Care at High-Quality Hospitals. J Am Coll Surg 226:22-29
Kozlik, Petr; Goldman, Radoslav; Sanda, Miloslav (2018) Hydrophilic interaction liquid chromatography in the separation of glycopeptides and their isomers. Anal Bioanal Chem 410:5001-5008

Showing the most recent 10 out of 1120 publications